Trial Profile
A Retrospective study of the efficacy of Infliximab and Adalimumab with the addition of an Immunomodulator in patients with Inflammatory Bowel Disease from the IBD center
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 14 Dec 2016
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary) ; Infliximab (Primary) ; Azathioprine; Mercaptopurine; Methotrexate; Tioguanine
- Indications Inflammatory bowel diseases
- Focus Therapeutic Use
- 14 Dec 2016 New trial record
- 19 Oct 2016 Results presented at the 24th United European Gastroenterology Week